Search
Tempest Therapeutics Inc
TPSTAdd to Watchlist
1.110USD
+0.010+0.91%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
16.44MMarket Cap
0.03P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.91%
5 Days
-11.55%
1 Month
-27.45%
6 Months
-61.32%
Year to Date
-61.32%
1 Year
-83.68%
Key Figures
1.100Open
1.130High
125.07KVolume
0.03P/E TTM
LossP/E Dynamic
--Dividend TTM
0.87%Turnover Ratio
1.100Prev. Close
1.080Low
114.40KTurnover
LossP/E Static
19.37P/B
0.00%Div Yield TTM
-200.87%ROA
12.23052wk High
0.30Volume Ratio
-41.84MNet Profit
14.34MShares
32.2064EPS TTM
-1.78Beta
-721.00%ROE
1.50052wk Low
4.55%Amplitude
--Gross Margin
16.44MMarket Cap
-4.05Reward/Risk
5.95%Risk Rate
TradingKey Stock Score of Tempest Therapeutics Inc
Currency: USD Updated: 2026-06-30Key Insights
Tempest Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 218 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Tempest Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Tempest Therapeutics Inc Highlights
StrengthsRisks
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Overvalued
The company’s latest PE is 0.03, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 4.51M shares, increasing 44.27% quarter-over-quarter.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
11.000
Target Price
+900.00%
Upside Space
Tempest Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Tempest Therapeutics Inc Info
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Ticker SymbolTPST
CompanyTempest Therapeutics Inc
CEO
Websitehttps://www.tempesttx.com/
Related Instruments
-2.50%
-1.79%
-1.22%
-0.57%
-0.73%
-0.56%
+0.44%
-0.86%
+0.01%
-2.42%
-0.58%
-1.64%
-0.76%
-1.77%
+1.01%
0.00%
-1.31%
+1.68%
+0.56%
+0.28%Popular Instruments
52146.500
-49.800 (-0.10%)
30086.800
-137.800 (-0.46%)
7471.800
-10.600 (-0.14%)
15300.000
-295.000 (-1.89%)
70736.000
-120.000 (-0.17%)
6293.400
-33.600 (-0.53%)
69.028
-0.893 (-1.28%)
289.360
+7.620 (+2.70%)
200.090
+5.120 (+2.63%)
4030.360
+23.080 (+0.58%)
FAQs
What is the current price of Tempest Therapeutics Inc (TPST)?
The current price of Tempest Therapeutics Inc (TPST) is 1.11.
What is the symbol of Tempest Therapeutics Inc?
The ticker symbol of Tempest Therapeutics Inc is TPST.
What is the 52-week high of Tempest Therapeutics Inc?
The 52-week high of Tempest Therapeutics Inc is 12.23.
What is the 52-week low of Tempest Therapeutics Inc?
The 52-week low of Tempest Therapeutics Inc is 1.50.
What is the market capitalization of Tempest Therapeutics Inc?
The market capitalization of Tempest Therapeutics Inc is 15.92M.
Is Tempest Therapeutics Inc (TPST) currently rated as Buy, Hold, or Sell?
According to analysts, Tempest Therapeutics Inc (TPST) has an overall rating of Buy, with a price target of 11.00.
What is the Earnings Per Share (EPS TTM) of Tempest Therapeutics Inc (TPST)?
The Earnings Per Share (EPS TTM) of Tempest Therapeutics Inc (TPST) is -6.33.